Pharmaceutical Enterprise TOLMAR Selects Pilgrim Software's Integrated Quality & Compliance Solutions

Pharmaceutical Enterprise TOLMAR Selects Pilgrim Software's Integrated Quality & Compliance Solutions
TAMPA, Fla.--(BUSINESS WIRE)--Pilgrim Software, Inc., a world-leading provider of Enterprise Risk, Compliance and Quality Management (ERCQM) software solutions, today announced that TOLMAR Inc., a Colorado-based pharmaceutical research, development, manufacturing and commercial operations company, has named Pilgrim as its automated risk, compliance and quality management systems provider.
TOLMAR will implement Pilgrim's integrated solutions for Document Management and Corrective & Preventive Action (CAPA) management. With the Pilgrim platform in place, the company will strengthen and sustain its ongoing compliance while improving operational efficiencies and cost containment efforts.

In addition to the document and CAPA management systems, TOLMAR will gain rapid data visibility and have total control over the format, appearance, and context of all quality reports using Pilgrim's SmartInsightTM Report Writer. This solution allows business users to instantly create professional, custom log reports that they can save and reuse whenever they wish.

"TOLMAR is adapting this automated, integrated solution model as we prepare our business for the future," said Francisco Gutierrez, Vice President of Quality & Site Operations for TOLMAR. "We identified the need to enhance our QA procedures and workflow with what Pilgrim provides - a fully integrated process that will greatly improve efficiencies and allow enterprise-wide visibility into key quality and compliance data in real time and across all functions."

"With the robust flexibility and scalability tools built into our solutions, Pilgrim will provide TOLMAR an effective framework for continuous improvement under one quality system platform," said Prashanth Rajendran, Pilgrim's Chief Operating Officer. "Both the document and CAPA solutions, in tandem with the enhanced reporting visibility, will elevate the harmonization and streamlining of TOLMAR's processes that increase efficiency and enable quicker response to internal and external needs and expectations."

About TOLMAR

TOLMAR is a northern Colorado based pharmaceutical research, development, manufacturing and commercial operations company. TOLMAR develops and manufacturers both proprietary and generic pharmaceutical products with specific focus in therapeutic areas of dental, dermatology, and oncology. TOLMAR provides our customers with a competitive and sustainable combination of product development and commercial services. Our strengths include a proven development, clinical, regulatory and manufacturing infrastructure with highly trained and experienced staff. For more information about the company, visit www.tolmar.com.

About Pilgrim Software, Inc.

Pilgrim Software, Inc. is a world-leading provider of Enterprise Risk, Compliance and Quality Management solutions for global organizations. Through its integrated platform, Pilgrim helps organizations manage industry and regulatory compliance, address potential risks, reduce manufacturing costs and improve customer satisfaction. Pilgrim has been named North American Enterprise Compliance & Quality Management Company of the Year - Best Practices by Frost & Sullivan, and winner of its 2010 North American Best-In-Class Customer Value Enhancement Award in the Enterprise Risk, Compliance and Quality Management Market for the Life Sciences Industry. For more information, visit Pilgrim Software's website at www.pilgrimsoftware.com.


Contacts
Pilgrim Software, Inc., Tampa
Sandy Carson, 813-915-1663

 

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.